Medscape (3/25, Busko, 201K) reports that research indicated that “compared with stopping dual antiplatelet therapy (DAPT) at 12 months, extending therapy to 30 months reduced the risk of stent thrombosis and MI but also increased the risk of mild to moderate bleeding in patients who had a coronary stent implanted—whether this followed an initial MI or stable angina.” .
HCRI's Executive Director, Cardiometabolic Trials, Christopher Cannon presents the need for triple therapy in patients with AFib and PCI or ACS at ACC 2015.
Dr. Christopher Cannon discusses a new kind of cholesterol lowering drug.
Dr. Robert Yeh discusses the DAPT Trial results in patients presenting with versus without acute coronary syndromes at ACC 2015
Dr. Robert Yeh presents on the Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients with and without Myocardial Infarction at ACC 2015.